FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status

How Insurers Use Copay Accumulator Programs to Undermine Drug Assistance for Patients

This article investigates how health insurers use "copay accumulator" programs to prevent drug manufacturer copay assistance coupons from co

Vets issue urgent warning to pet owners as flesh-eating screwworm spreads through Texas and New Mexico

Australia news live: Telstra warns of ‘secondary issue’ after yesterday’s network outage; trains in regional Victoria cancelled again

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

UPMC returns to profitability with $380M profit after two years of losses

UPMC returned to profitability in fiscal year 2024-2025 with a profit of over $380 million, reversing two years of historically large losses

How Front-Desk Friction Drives Patient Churn Despite High Clinical Satisfaction

A primary-care patient rated her physician highly but left the practice due to poor front-desk experiences — specifically, long phone wait t